Johnson & Johnson Says Its Covid Shot Neutralizes Delta Variant.

Johnson & Johnson Says Its Covid Shot Neutralizes Delta Variant

Manufacturers have been crafting updated versions of their shots to directly target the emerging variants

Johnson & Johnson said that its single-shot coronavirus vaccine neutralizes the fast-spreading delta variant and provides durable protection against infection more broadly.

The company said in a statement Thursday that recipients of its vaccine produced strong neutralizing antibodies over the course of at least eight months against all variants including delta, which was first seen in India and has been spreading around the globe.

Delta is expected to become the dominant strain in the U.S. in the coming weeks, according to the Centers for Disease Control and Prevention. The J&J shot provides less protection initially than messenger RNA vaccines from Pfizer Inc. and Moderna Inc., and experts have been discussing whether some people may need booster shots to keep the virus at bay long-term.

"We're extremely happy, actually, and confident there's no need for the booster at the moment and we're protected against different strains," said Johan Van Hoof, J&J's global head of infectious diseases and vaccines, in an interview.

The shot neutralized the delta variant within 29 days of a first dose, and protection matured and improved over time, the company said.

With the latest data in hand, Van Hoof said J&J doesn't believe people who have been given its vaccine should need a booster within a year of having gotten it. "And if a boost is needed," he said, "we don't think we'll need to change the formulation."

Scientists and some vaccine manufacturers have been crafting updated versions of their shots to directly target the emerging variants, which have proved to be significantly more transmissible than the original virus that first emerged in Wuhan, China, in late 2019.

The continued evolution of the pathogen, however, is creating an ever-moving target, leading some to evaluate whether additional doses of existing immunizations may provide more protection.

The findings J&J disclosed Thursday were from two studies.

The company evaluated the blood samples of eight participants in its late-stage clinical trial of the vaccine to assess neutralizing antibodies produced against the delta variant. Dan Barouch of Beth Israel Deaconess Medical Center evaluated the durability of the immune response in 20 participants of an early-stage vaccine study.

More robust results will be published in bioRxiv, an online research depository, the company said.

Two-Shot Regimen

Data released by the company showed antibody counts, known as titres, were substantially higher in response to the delta variant than the beta variant first detected in South Africa.

J&J said a second dose of its vaccine is known to increase a person's antibody count. The company plans to report efficacy data from a late-stage trial of a two-shot regimen at the end of August, Van Hoof said.

The company is also studying its vaccine's ability to create T cells, another gauge of its protective power. The shot produced increasing T cell immunity against the virus and its variants over eight months, according to Van Hoof.

J&J's shot has struggled to get broad traction amid production problems and after a brief pause in use as regulators investigated reports that some people suffered dangerous blood clots after receiving it. The pause was lifted after 10 days on April 23.

NDTV News

NDTV.com provides latest news from India and the world. Get today’s news headlines from Business, Technology, Bollywood, Cricket, videos, photos, live news coverage and exclusive breaking news from India.

https://www.ndtv.com/

Related news

Myanmar Junta Promises Elections In Two Years

Myanmar's junta chief said Sunday that elections would be held and a state of emergency lifted by August 2023, extending the military's initial timeline given when it deposed Aung San Suu Kyi six...

NDTV News

GOP lawmaker unveils bill to shed light on Biden family business dealings.

GOP lawmaker unveils bill to shed light on Biden family business dealings.

Rep. Michael Waltz, R-Fla,. and Fox News contributor Lara Trump question where money for Hunter Biden's art is coming from on 'Hannity.' #FoxNews #Hannity Subscribe to Fox News! Watch more Fox News Video: Watch Fox News Channel Live: FOX News Chan...

Biden SNAPS at reporter after confronted about U-turn asking vaccinated to wear masks.

Biden SNAPS at reporter after confronted about U-turn asking vaccinated to wear masks.

JOE Biden clashed with Fox News journalist Peter Doocy after the reporter reminded the president that he once said Americans don’t need to wear a mask if they are fully vaccinated. The heated exchange came just days after boffins at the Centers fo...

Space Command:  UK launches new defence against threats from space.

Space Command: UK launches new defence against threats from space.

The UK's Space Command, a joint effort comprised of the Royal Navy, British Army and Royal Air Force, will respond to growing threats from China and Russia. Military chiefs say we have to be alert to the risk of other countries developing anti-sat...

1 143

Border crisis an 'unprecedented, unmitigated disaster': Rep.

Border crisis an 'unprecedented, unmitigated disaster': Rep.

Louisiana Congressman Mike Johnson argues the migrant surge is a humanitarian, health and national security issue and says the Biden administration needs to step up 'immediately.' #FoxNews #FoxFriendsFirst Subscribe to Fox News! Watch more Fox New...

MTV turns 40!

MTV turns 40!

ABC News’ Will Ganss and Bruno del Granado look back at all the iconic moments that made MTV what it is today.

COVID-19: Data shows infections rise to 1 in 65 people for England.

COVID-19: Data shows infections rise to 1 in 65 people for England.

The data also shows hospitalisations among 15 to 24-year-olds are the highest they've been since the start of the pandemic across England. The Office for National Statistics data will limit confidence in the dashboard data which had shown a drop o...